blocking pge2-induced tumour repopulation abrogates bladder cancer chemoresistance 
cytotoxic chemotherapy effective debulking tumour masses initially; however patients tumours become progressively unresponsive multiple treatment cycles previous studies demonstrated cancer stem cells cscs selectively enriched chemotherapy enhanced survival1- reveal new mechanism bladder cscs actively contribute therapeutic resistance via unexpected proliferative response repopulate residual tumours chemotherapy cycles using human bladder cancer xenografts analyses demonstrate recruitment quiescent label-retaining pool cscs cell division response chemotherapy-induced damages similar mobilization normal stem cells wound repair4- chemotherapy effectively induces apoptosis associated prostaglandin e- pge2 release paradoxically promotes neighbouring csc repopulation repopulation can abrogated pge2-neutralizing antibody celecoxib drug-mediated blockade pge2 signalling vivo administration cyclooxygenase- cox2 inhibitor celecoxib effectively abolishes pge2 cox2-mediated wound response gene signature attenuates progressive manifestation chemoresistance xenograft tumours including primary xenografts derived patient resistant chemotherapy collectively findings uncover new underlying mechanism models progressive development clinical chemoresistance implicate adjunctive therapy enhance chemotherapeutic response bladder urothelial carcinomas abrogating early tumour repopulation 
